Reneo Pharmaceuticals, Inc. (RPHM) Bundle
A Brief History of Reneo Pharmaceuticals, Inc. (RPHM)
Company Formation
Company Formation
Reneo Pharmaceuticals, Inc. was founded in 2016, focusing on developing therapies for patients with rare mitochondrial diseases. The company is headquartered in San Diego, California.
Key Developments
In 2019, Reneo announced a partnership with Retrophin, Inc. for the development of its lead product, Reneo 1 (also referred to as Reneo's primary asset). In April 2021, the company initiated a Phase 2 clinical trial for Reneo 1.
Financial Performance
As of September 30, 2023, Reneo Pharmaceuticals reported total cash and cash equivalents of $38.5 million. This amount reflects a decrease from $55.2 million reported at the end of Q2 2023, primarily due to operational expenses.
Stock Performance
Reneo Pharmaceuticals has been publicly traded on the Nasdaq under the ticker symbol RPHM since 2021. As of October 2023, the stock price was approximately $5.72, representing a year-to-date increase of 25%.
Clinical Trials
Reneo’s lead candidate, Reneo 1, focuses on treating disorders associated with mitochondrial dysfunction. The Phase 2 trial aims to enroll approximately 100 patients across multiple sites. The company expects to report results in early 2024.
Investor Relations
In October 2023, Reneo Pharmaceuticals raised $20 million through a private placement of common stock. The proceeds are intended for further clinical development and other general corporate purposes.
Partnerships and Collaborations
Reneo has formed strategic collaborations with academic institutions and industry partners to bolster its research capabilities. The company collaborates with Stanford University on mitochondrial biology research and with various biotech firms for complementary technology development.
Research and Development Expenditure
For the fiscal year ending December 31, 2022, Reneo Pharmaceuticals reported R&D expenses of $18 million, compared to $12 million in the previous fiscal year.
| Fiscal Year | Cash and Cash Equivalents | R&D Expenses | Stock Price | Partnerships |
|---|---|---|---|---|
| 2023 (Q3) | $38.5 million | $18 million | $5.72 | Retrophin, Stanford |
| 2022 | $55.2 million | $12 million | N/A | Multiple biotech firms |
Market Focus
Reneo Pharmaceuticals primarily targets rare disease markets, particularly those associated with mitochondrial dysfunctions such as primary mitochondrial myopathy and Leigh syndrome.
Recent Updates
In September 2023, Reneo presented at the Bio Investor Forum, highlighting progress in its clinical trials and discussions on future therapeutic strategies.
A Who Owns Reneo Pharmaceuticals, Inc. (RPHM)
Corporate Structure
Reneo Pharmaceuticals, Inc. (RPHM) is a clinical-stage biopharmaceutical company primarily focused on developing treatments for mitochondrial diseases. The company trades under the ticker symbol RPHM on the NASDAQ.
Major Shareholders
As of the latest filings, the ownership structure of Reneo Pharmaceuticals is comprised of institutional investors, individual shareholders, and company insiders.
| Shareholder Type | Percentage Ownership | Number of Shares Owned | Last Update |
|---|---|---|---|
| Institutional Investors | 70.5% | 10,469,000 | September 2023 |
| Company Insiders | 15.3% | 2,260,000 | September 2023 |
| Retail Investors | 14.2% | 2,080,000 | September 2023 |
Top Institutional Investors
The following are the top institutional shareholders of Reneo Pharmaceuticals:
| Institution | Shares Owned | Percentage of Total Shares | Last Update |
|---|---|---|---|
| BlackRock, Inc. | 1,800,000 | 12.1% | September 2023 |
| The Vanguard Group, Inc. | 1,500,000 | 10.1% | September 2023 |
| FMR LLC (Fidelity) | 1,200,000 | 8.1% | September 2023 |
Company Insiders
Key insiders having substantial ownership include:
| Name | Position | Shares Owned | Percentage of Holdings | Last Update |
|---|---|---|---|---|
| Joseph M. Dwyer | Chief Executive Officer | 1,000,000 | 9.0% | September 2023 |
| Michael D. DeMarco | Chief Financial Officer | 800,000 | 7.0% | September 2023 |
| Sharon R. Chang | Board Member | 460,000 | 4.0% | September 2023 |
Market Capitalization
The market capitalization of Reneo Pharmaceuticals as of September 2023 is approximately $140 million.
Stock Performance
The stock performance metrics include:
| Metric | Value | Date |
|---|---|---|
| Current Stock Price | $6.50 | September 2023 |
| 52-week High | $8.50 | July 2023 |
| 52-week Low | $3.00 | November 2022 |
| Average Volume (30 days) | 150,000 shares | September 2023 |
Recent Developments
In recent months, Reneo Pharmaceuticals has secured $30 million in funding through a Series B financing round, intended to expedite the ongoing clinical trials for its lead candidate, REN001.
Reneo Pharmaceuticals, Inc. (RPHM) Mission Statement
Corporate Vision
Reneo Pharmaceuticals, Inc. is committed to becoming a leader in the development of innovative therapies for patients with rare diseases and unmet medical needs. The corporate vision focuses on advancing treatments in metabolic and mitochondrial diseases.
Core Values
- Innovation: Striving to innovate the field of pharmaceuticals through research and development.
- Integrity: Maintaining the highest ethical standards in all aspects of the organization.
- Patient-Centric: Prioritizing the needs of patients in every decision and action taken.
- Collaboration: Fostering partnerships with researchers, healthcare professionals, and patients.
Mission Statement Details
The mission of Reneo Pharmaceuticals is to offer comprehensive solutions and develop effective treatments for patients suffering from mitochondrial diseases, specifically focusing on:
- Research and Development of new therapies.
- Advancing clinical trials to better understand treatment efficacy.
- Improving the quality of life for patients through innovative approaches.
Financial Overview
As of the third quarter of 2023, Reneo Pharmaceuticals reported the following financial figures:
| Financial Metric | Amount (in millions USD) |
|---|---|
| Revenue | 0.0 |
| Operating Expenses | 12.5 |
| Net Loss | -10.5 |
| Cash and Cash Equivalents | 50.0 |
| Market Capitalization | 120.0 |
Pipeline Development
Reneo Pharmaceuticals is advancing several key product candidates targeting genetic diseases associated with mitochondrial dysfunction:
- Rene-050: Currently in Phase 2b clinical trials.
- Rene-100: Expected to enter Phase 1 trials in early 2024.
- Rene-200: Preclinical stage with completion projected in 2025.
Commitment to Patients
Reneo Pharmaceuticals takes pride in its outreach efforts to the patient community:
- Establishing patient support programs.
- Hosting educational webinars and information sessions.
- Collaborating with patient advocacy groups to enhance awareness.
How Reneo Pharmaceuticals, Inc. (RPHM) Works
Company Overview
Reneo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for mitochondrial diseases. The company aims to improve patient outcomes through innovative approaches to treatment.
Business Model
Reneo operates primarily through a model focused on drug development, with emphasis on:
- Research and Development (R&D) investments
- Clinical trials for drug efficacy and safety
- Partnerships and collaborations with research institutions
- Seeking regulatory approvals for its drug candidates
Financial Performance
As of the latest financial reports, Reneo Pharmaceuticals, Inc. shows the following financial data:
| Financial Metric | Value (as of Q3 2023) |
|---|---|
| Total Revenue | $0 million |
| Net Loss | ($22.4 million) |
| Total Assets | $75.1 million |
| Total Liabilities | $15.3 million |
| Cash and Cash Equivalents | $35.6 million |
| Market Capitalization | $102 million |
Clinical Pipeline
Reneo’s clinical pipeline primarily includes:
- Reneo-100: Phase 2 clinical trial for patients with primary mitochondrial myopathy.
- Reneo-200: Early-stage development for additional mitochondrial disorders.
Partnerships and Collaborations
Reneo has established various collaborations to enhance its research output, including:
- Partnership with academic institutions for joint research.
- Collaboration with contract research organizations (CROs) to facilitate clinical trials.
Stock Performance
As of October 2023, RPHM’s stock performance is detailed below:
| Date | Stock Price (USD) | Volume |
|---|---|---|
| October 1, 2023 | $2.10 | 150,000 |
| October 15, 2023 | $1.85 | 200,000 |
| October 31, 2023 | $2.00 | 180,000 |
Market Opportunities
The potential market for mitochondrial disease treatments includes:
- Increasing prevalence of mitochondrial disorders globally.
- Advancements in genetic research contributing to better diagnosis.
- Growing interest from investors in rare disease therapeutics.
Regulatory Environment
Reneo operates under the oversight of regulatory bodies such as the:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
Recent Developments
Recent milestones for Reneo include:
- Successful completion of Phase 2 trials for Reneo-100.
- Positive feedback from FDA on clinical development plans.
How Reneo Pharmaceuticals, Inc. (RPHM) Makes Money
Revenue Streams
Reneo Pharmaceuticals, Inc. primarily generates revenue through the development and commercialization of its drug candidates. Their main focus is on therapies for rare genetic diseases that affect mitochondrial function.
Product Candidates
As of October 2023, Reneo is advancing several product candidates in clinical trials. The lead candidate, Rheos Therapeutics, targets disorders linked to mitochondrial dysfunction. The company's pipeline includes:
- Reneo's lead drug candidate: Reneo-001, currently in Phase 2 clinical trials.
- Expected market entry: 2025, contingent upon successful clinical outcomes.
- Potential market size: Estimated at $1.5 billion annually in the United States alone for rare mitochondrial diseases.
Financial Performance
Reneo Pharmaceuticals reported the following financial figures for Q3 2023:
| Financial Metric | Q3 2023 Amount (in $ millions) |
|---|---|
| Revenue | $0.0 |
| R&D Expenses | $11.2 |
| SG&A Expenses | $5.3 |
| Net Loss | $16.5 |
| Cash and Cash Equivalents | $30.1 |
Funding and Investments
Reneo Pharmaceuticals has secured various funding rounds to support its operations:
- IPO in 2021: Raised $40 million.
- Series A Funding: $25 million raised in 2020.
- Series B Funding: $30 million raised in 2022.
Partnerships and Collaborations
Strategic collaborations further bolster Reneo's potential revenue:
- Collaboration with major biotech firms: Includes partnerships for co-development and licensing.
- Royalty agreements: Potential for royalties from partnered drug sales.
Market Potential and Competitors
The pharmaceutical landscape for mitochondrial diseases includes notable competitors:
- Company A: Projected annual revenues of $300 million.
- Company B: Current market value of $2.4 billion.
- Reneo's competitive edge: Focus on niche market with few existing targeted therapies.
Future Outlook
The financial projections for Reneo Pharmaceuticals indicate a promising trajectory:
- Projected Revenue (2026): Estimated at $100 million post-commercialization of Reneo-001.
- Growth Rate: Anticipated annual growth of 15% in subsequent years, assuming successful market entry.
- Investment potential: Attracts interest due to innovative pipeline and aligned focus on rare diseases.
Reneo Pharmaceuticals, Inc. (RPHM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support